stockrow
Friday 6 November 2026
Export NKGN’s income statement to Excel — free account
NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00.
- EPS
- +232.0%
- Free cash flow
- +28.7%
Quarter to March 2025, against a year earlier
0.01
0.00
0.00%
Follow NKGN
Alert me
NKGen Biotech, Inc. (NKGN) P/E ratio
NKGen Biotech, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 241× (May 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 241×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CALC CalciMedica Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| NKGN NKGen Biotech, Inc. | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)